Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The ...
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $36.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback